HIGHLIGHTS
- who: Thomas E. van der Schalk from the The study was designed to assess the performance of a rapid screening test, the Cepheid GeneXpert PA assay, in patients at risk of developing VAPDuring February, September, ETA samples were collected from mechanically ventilated adult patients admitted to the intensive care unit (ICU) at the Antwerp University Hospital (UZA), either for surveillance cultures or as routine samples obtained in patients with a suspected (pulmonary) infection (Fig., ). Clinical patient data regarding the development of VAP was also collected in have published the Article: Evaluation of GeneXpert PA assay compared to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.